Efficacy of 1 week and 2 weeks standard triple therapy for the eradication of clarithromycin-sensitive helicobacter pylori infection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0005309

Enrollment

180

Registered

2020-08-11

Start date

2020-08-06

Completion date

Unknown

Last updated

2020-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Patients are randomly allocated to receive a 7-days or 14-days standard triple therapy (rabeprazole 20mg, amoxicillin 1.0g, clarithromycin 500mg, each administered twice daily for 7 days or 14

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults older than 19 and younger than 80 are eligible. Patients with peptic ulcer disease, gastric neoplasms, gastric MALT lymphoma, chronic gastritis with Helicobacter pylori infection are included in the study.

Exclusion criteria

Exclusion criteria: Patients with previous Helicobacter pylori eradication therapy, patients with stomach or esophageal surgery, patients with pregnancy or lactation, patients with renal or hepatic dysfunction, patients with previous history of allergy or hypersensitivity reactions to drugs, patients with infectious mononucleosis, Patients with hematologic disorders, patients with nervous system disease are excluded.

Design outcomes

Primary

Measure	Time frame
erdiaction rate	—

Secondary

Measure	Time frame
adverse events;compliance	—

Countries

Korea, Republic of

Contacts

Public ContactJin Lee

Inje University Haeundae Paik Hospital

Outcome results